Skip to main content
Erschienen in: Internal and Emergency Medicine 2/2017

01.03.2017 | IM - ORIGINAL

Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care

verfasst von: Irene Cacciola, Riccardo Scoglio, Angela Alibrandi, Giovanni Squadrito, Giovanni Raimondo, SIMG-Messina Hypertransaminasemia Study Group

Erschienen in: Internal and Emergency Medicine | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The evaluation of serum liver enzyme levels is the most used surrogate marker of liver injury in clinical practice. The prevalence and association of abnormal enzyme values with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, and with other major causes of liver damage (obesity, diabetes, dyslipidemia, and alcohol abuse) were evaluated in individuals attending the surgeries of 14 general practitioners (GPs) working in Messina. Alanine-amino-transferase, aspartate-amino-transferase, and gamma-glutamyl-transpeptidase measurements were measured in 7816 individuals consecutively attending the GP surgeries between January 1, 2011 and June 30, 2012. Five-thousand-eight-hundred-six subjects (74.3 %) had the tests performed, and 1189 of them (20.5 %) showed increased liver enzyme levels. Sixty-nine of these 1189 individuals (5.8 %) were HCV positive and 12 HBV positive (1 %), 755 (63.5 %) were overweight or obese, 288 (24.2 %) had diabetes, and 351 (29.5 %) had dyslipidemia; 262 (22 %) drank >2 alcoholic units/day. Overall, 57 % of individuals with abnormal liver enzymes had multiple possible causes of liver disease, 28 % one cause, and 15 % no apparent cause. In conclusion, this study shows that 1/5 of individuals attending GP surgeries have altered liver biochemistry and that overweight and metabolic disorders have become the major causes of liver damage even in South Italy, where HBV and HCV were endemic in the past century. Notably, many HCV and HBV patients are still unaware of their infected status, and GPs are essential for their timely identification.
Literatur
1.
Zurück zum Zitat Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58:593–608CrossRefPubMed Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58:593–608CrossRefPubMed
2.
Zurück zum Zitat Donato F, Gelatti U, Limina RM, Fattovich G (2006) Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 25:3756–3770CrossRefPubMed Donato F, Gelatti U, Limina RM, Fattovich G (2006) Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 25:3756–3770CrossRefPubMed
3.
Zurück zum Zitat Friedman LS, Dienstag JL, Watkins E, Hinkle CA, Spiers JA, Rieder SV, Huggins CE (1987) Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann Intern Med 107:137–144CrossRefPubMed Friedman LS, Dienstag JL, Watkins E, Hinkle CA, Spiers JA, Rieder SV, Huggins CE (1987) Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann Intern Med 107:137–144CrossRefPubMed
4.
Zurück zum Zitat Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1–10CrossRefPubMed Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1–10CrossRefPubMed
5.
Zurück zum Zitat Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, Bruno S, Mangano C, Polito I, Amato F, Cotichini R, Stroffolini T, Mele A, Group ACEC (2005) Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 41:1151–1159CrossRef Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, Bruno S, Mangano C, Polito I, Amato F, Cotichini R, Stroffolini T, Mele A, Group ACEC (2005) Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 41:1151–1159CrossRef
6.
Zurück zum Zitat Diez-Vallejo J, Comas-Fuentes A (2011) Asymptomatic hypertransaminasemia in patients in primary care. Rev Esp Enferm Dig 103:530–535CrossRefPubMed Diez-Vallejo J, Comas-Fuentes A (2011) Asymptomatic hypertransaminasemia in patients in primary care. Rev Esp Enferm Dig 103:530–535CrossRefPubMed
7.
Zurück zum Zitat Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, Cristianini G (1994) Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 20:1442–1449CrossRefPubMed Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, Cristianini G (1994) Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 20:1442–1449CrossRefPubMed
8.
Zurück zum Zitat Loguercio C, Tiso A, Cotticelli G, Blanco Cdel V, Arpino G, Laringe M, Napoli L, Piccinocchi G, Bonfrate L, Grattagliano I, Ubaldi E, Portincasa P (2011) Management of chronic liver disease by general practitioners in southern Italy: unmet educational needs. Dig Liver Dis 43:736–741CrossRefPubMed Loguercio C, Tiso A, Cotticelli G, Blanco Cdel V, Arpino G, Laringe M, Napoli L, Piccinocchi G, Bonfrate L, Grattagliano I, Ubaldi E, Portincasa P (2011) Management of chronic liver disease by general practitioners in southern Italy: unmet educational needs. Dig Liver Dis 43:736–741CrossRefPubMed
9.
Zurück zum Zitat Bellentani S, Scaglioni F, Ciccia S, Bedogni G, Tiribelli C (2010) HCV, HBV and alcohol—the Dionysos study. Dig Dis 28:799–801CrossRefPubMed Bellentani S, Scaglioni F, Ciccia S, Bedogni G, Tiribelli C (2010) HCV, HBV and alcohol—the Dionysos study. Dig Dis 28:799–801CrossRefPubMed
10.
Zurück zum Zitat Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, Scolastico C, Onofrio M, Imparato M, Filippini P (2005) The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 75:522–527CrossRefPubMed Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, Scolastico C, Onofrio M, Imparato M, Filippini P (2005) The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 75:522–527CrossRefPubMed
11.
Zurück zum Zitat Loguercio C, Federico A, Bianchi C, D'Auria M, Tallarico A, Bianco M, Fiorito R, Del Vecchio Blanco C, Stroffolini T (2007) Drinking habits and risk of altered liver enzymes in the general population of a rural area in Southern Italy. Dig Liver Dis 39:748–752CrossRefPubMed Loguercio C, Federico A, Bianchi C, D'Auria M, Tallarico A, Bianco M, Fiorito R, Del Vecchio Blanco C, Stroffolini T (2007) Drinking habits and risk of altered liver enzymes in the general population of a rural area in Southern Italy. Dig Liver Dis 39:748–752CrossRefPubMed
12.
Zurück zum Zitat Panel of experts (1998) Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. Obes Res 6(Suppl 2):51S–209S Panel of experts (1998) Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. Obes Res 6(Suppl 2):51S–209S
13.
Zurück zum Zitat Stroffolini T, Sagnelli E, Mele A, Craxi A, Almasio P, Italian Hospitals Collaborating G (2004) The aetiology of chronic hepatitis in Italy: results from a multicentre national study. Dig Liver Dis 36:829–833CrossRefPubMed Stroffolini T, Sagnelli E, Mele A, Craxi A, Almasio P, Italian Hospitals Collaborating G (2004) The aetiology of chronic hepatitis in Italy: results from a multicentre national study. Dig Liver Dis 36:829–833CrossRefPubMed
14.
Zurück zum Zitat Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M (2013) Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 13:181CrossRefPubMedPubMedCentral Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M (2013) Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 13:181CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Wedemeyer H, Dore GJ, Ward JW (2015) Estimates on HCV disease burden worldwide—filling the gaps. J Viral Hepat 22(Suppl 1):1–5CrossRef Wedemeyer H, Dore GJ, Ward JW (2015) Estimates on HCV disease burden worldwide—filling the gaps. J Viral Hepat 22(Suppl 1):1–5CrossRef
16.
17.
Zurück zum Zitat Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schreter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarcuska P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren T, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H (2015) The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm–volume 2. J Viral Hepat 22(Suppl 1):26–45CrossRefPubMed Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schreter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarcuska P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren T, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H (2015) The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm–volume 2. J Viral Hepat 22(Suppl 1):26–45CrossRefPubMed
18.
Zurück zum Zitat Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G (2011) Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 54:145–152CrossRefPubMed Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G (2011) Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 54:145–152CrossRefPubMed
19.
Zurück zum Zitat Bellentani S, Scaglioni F, Marino M, Bedogni G (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28:155–161CrossRefPubMed Bellentani S, Scaglioni F, Marino M, Bedogni G (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28:155–161CrossRefPubMed
20.
Zurück zum Zitat Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R (2010) Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51:595–602CrossRefPubMed Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R (2010) Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51:595–602CrossRefPubMed
21.
Zurück zum Zitat Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P (2013) A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 58:1218–1229CrossRefPubMed Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P (2013) A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 58:1218–1229CrossRefPubMed
22.
Zurück zum Zitat Bedogni G, Miglioli L, Masutti F, Castiglione A, Croce LS, Tiribelli C, Bellentani S (2007) Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 46:1387–1391CrossRefPubMed Bedogni G, Miglioli L, Masutti F, Castiglione A, Croce LS, Tiribelli C, Bellentani S (2007) Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 46:1387–1391CrossRefPubMed
23.
Zurück zum Zitat Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44–52CrossRefPubMed Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44–52CrossRefPubMed
24.
Zurück zum Zitat Grattagliano I, Ubaldi E, Bonfrate L, Portincasa P (2011) Management of liver cirrhosis between primary care and specialists. World J Gastroenterol 17:2273–2282CrossRefPubMedPubMedCentral Grattagliano I, Ubaldi E, Bonfrate L, Portincasa P (2011) Management of liver cirrhosis between primary care and specialists. World J Gastroenterol 17:2273–2282CrossRefPubMedPubMedCentral
Metadaten
Titel
Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care
verfasst von
Irene Cacciola
Riccardo Scoglio
Angela Alibrandi
Giovanni Squadrito
Giovanni Raimondo
SIMG-Messina Hypertransaminasemia Study Group
Publikationsdatum
01.03.2017
Verlag
Springer International Publishing
Erschienen in
Internal and Emergency Medicine / Ausgabe 2/2017
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-016-1535-2

Weitere Artikel der Ausgabe 2/2017

Internal and Emergency Medicine 2/2017 Zur Ausgabe

CE - MEDICAL ILLUSTRATION

Wellens’ syndrome

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.